Rentschler Biopharma is constructing a new production facility at its headquarters in Laupheim, Germany. This is the company’s biggest investment at this location so far. The new facility will be 3,400 square meters and will have three media tanks and six buffer tanks. It will also have special areas to meet strict hygiene and safety standards. The facility will connect to the existing systems for making and processing products. It will also have automation and ergonomic workstations to make processes faster and more efficient. This supports the company’s sustainability goals. Benedikt von Braunmühl, the CEO, said the company is investing in infrastructure to ensure stability and growth. He also said the new facility shows their commitment to Laupheim and to Germany and Europe as leading biotech hubs. Christiane Bardroff, the COO, said the new facility will make processes more efficient and secure. It will also provide a state-of-the-art working environment for employees. The new facility is expected to be operational by 2028.